Atherosclerosis Plus

Official Twitter account of Atherosclerosis Plus, an open access journal published by Elsevier. Facebook Page:

[Atherosclerosis Plus @ATH_Plus]

How does time since last meal affect lipoprotein and inflammatory biomarkers?
In healthy young adults, Jensen et al. found that six VLDL particle subclasses rose 11–429% within 2–4h after breakfast, with IL-6 increasing ~325% at 10h.
🔗 https://t.co/67j9tbopFH
@society_eas

[Atherosclerosis Plus @ATH_Plus]

From the archive: HDL-replacement therapy remains a fascinating translational field.
This review discusses traditional and emerging clinical applications of HDL-based approaches, from lipid biology to therapeutic perspectives.
🔗https://t.co/viNoPuusEn

[Atherosclerosis Plus @ATH_Plus]

Inflammation and metabolic dysfunction are key drivers of atherosclerosis. A new study in Ath Plus shows that the C-reactive protein–triglyceride–glucose index is independently associated with peripheral artery disease in U.S. adults.
🔗https://t.co/ZSbZd6aCR5
@society_eas

[European Atherosclerosis Society @society_eas]

Familial hypercholesterolaemia (FH) is a common genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol (LDL-C) concentrations, which increase the risk of premature atherosclerotic cardiovascular disease (ASCVD).

FH affects around 1 in 300 people worldwide, while the more severe form, Homozygous FH (HoFH), affects about 1 in 300,000 people and can lead to serious cardiovascular complications already in childhood.

🚨 Early diagnosis and treatment can dramatically improve — and even normalize — life expectancy. Yet, fewer than 10% of affected children in Europe are currently identified.

The European Atherosclerosis Society (EAS) consensus statement on FH in children and adolescents highlights:

✔️ Improved diagnostic criteria
✔️ Earlier treatment initiation — sometimes from age 6
✔️ Lower LDL-C treatment targets
✔️ New lipid-lowering therapies
✔️ Updated treatment algorithms
✔️ Better transition from paediatric to adult care

The statement emphasizes one key message: reducing lifelong exposure to high LDL-C is critical to protecting cardiovascular health from an early age.

Read the full publication: https://t.co/33zCtcaqaX
To the press release: https://t.co/iz2gzPVQd7
To the key messages: https://t.co/RSrAy5VcUd

[Atherosclerosis Plus @ATH_Plus]

Can environmental pollution shape cardiovascular risk through autoimmunity?
This new geospatial study shows that hotspots of anti-apoA-I autoantibodies overlap with areas of higher air/soil pollution and lower life expectancy in Geneva.
🔗https://t.co/9uRS6oq9zn
@society_eas

[Atherosclerosis Plus @ATH_Plus]

New Expert Consensus on Lipoprotein(a) in the Gulf Countries highlights the urgent need to integrate #Lp(a) into cardiovascular risk assessment!
🔗https://t.co/8PQXBqjWlQ
@society_eas

[Atherosclerosis Plus @ATH_Plus]

@EstebanDL @society_eas https://t.co/DcDDXapp7Y

[Atherosclerosis Plus @ATH_Plus]

Same condition, different risks.
In hypercholesterolemia, Lp(a) is a key driver of CAD in women—but not in men, where smoking and hypertension prevail.
🔗https://t.co/DcDDXapp7Y
@society_eas

[Atherosclerosis Plus @ATH_Plus]

Even among adults with normal glucose and TG levels, a higher #TyG index is linked to systemic inflammation and arterial stiffness — especially in women. #TyG as an early marker of cardiometabolic risk.
https://t.co/PbgqV6VlBs
@society_eas

[Atherosclerosis Plus @ATH_Plus]

CNN3 emerges as a key player in atherosclerosis: it is increased in plaques and in patients’ blood, and promotes VSMC proliferation and migration. Circulating CNN3 also shows promise as a diagnostic biomarker
🔗https://t.co/vSGTT48Sko

[Atherosclerosis Plus @ATH_Plus]

PCSK9 inhibition does not alter monocyte subset distribution in high-risk patients, but reshapes monocyte–lipoprotein interactions. An Lp(a)–intermediate monocyte link emerges, while KIV-2 repeats appear to drive inflammation more than Lp(a) levels.
https://t.co/BdovbPMpHn

[Atherosclerosis Plus @ATH_Plus]

Real-world evidence confirms bempedoic acid delivers ≥20% LDL-C reduction, consistent with RCTs. Effective both with statins and in statin-intolerant patients. No new safety signals observed. https://t.co/5TUAVps8F8
@society_eas

[Atherosclerosis Plus @ATH_Plus]

Calciprotein particles (CPPs), formed during calcium–phosphate overload, impair autophagic flux in vascular cells via lysosomal dysfunction. A mechanistic link between chronic mineral stress and vascular dysfunction
https://t.co/8k7eyimK5p
@society_eas

[Atherosclerosis Plus @ATH_Plus]

HIV is no longer just a chronic infection—it’s a cardiovascular risk factor. This population-based study in Uganda finds higher arterial stiffness and ~2x increased odds among PLWH. Time to integrate CVD screening into HIV care.
https://t.co/hjbMQFmYQW

[Atherosclerosis Plus @ATH_Plus]

Is there a link between non-steroidal anti-inflammatory drugs and cardiovascular risk in patients with inflammatory arthritis?
🔗https://t.co/x04JYYrU45
@society_eas

[Atherosclerosis Plus @ATH_Plus]

Beyond lipid regulation, VSMC-derived PCSK9 drives vascular inflammation, phenotypic switching, and plaque progression. PCSK9 inhibition may stabilize plaques beyond LDL lowering.
🔗https://t.co/Q8lfWkmGLZ
@society_eas

[Atherosclerosis Plus @ATH_Plus]

Which metabolic biomarkers drive arterial calcification? A new study using NMR profiling, MR, and large cohorts identifies fatty acid ratios causally linked to lower CAC and a male-specific association for GlycA, with implications for CHD risk.
https://t.co/4anACRjwjO

[Atherosclerosis Plus @ATH_Plus]

Why do some atherosclerotic plaques become dangerous?
This new study shows that G9A, an epigenetic enzyme, promotes vascular calcification by activating BMP2 signaling and pushing smooth muscle cells to change identity.
🔗https://t.co/EK1duCfNgt
@society_eas

[Atherosclerosis Plus @ATH_Plus]

New research on unstable carotid plaques reveals that abnormal phosphatidylcholine metabolism drives plaque instability by activating ER stress pathways (especially PERK/CHOP).
🔗https://t.co/GLAaDNpMOZ
@society_eas

[Atherosclerosis Plus @ATH_Plus]

Real-world use of bempedoic acid was associated with a 21% LDL-C reduction and BA+ezetimibe with a 33% reduction at 3 months.
Over 12 months, the proportion of patients achieving LDL-C <70 mg/dL increased from 6–9% at baseline to 18–28%.
https://t.co/fGdqPMBv6n
@society_eas